Effects of Vortioxetine in Mild Cognitive Impairment measured by Functional Magnetic Resonance Imaging - Vortioxetine in MCI

Medical University of Vienna0 个研究点目标入组 45 人开始时间: 2021年7月21日最近更新: 2021年10月8日

适应症

试验速览

暂无简介。

•1.Age 50-80 years
•2.Concern regarding a change in cognition by the subject, an informant, or a clinican
•3.Objective memory impairment for age and optionally impairment in other cognitive domains
•4.Hippocampal volume loss or medial temporal atrophy as evidenced by MRI
•5.Sufficient visual and auditory performance for neuropsychological testing
•6.Willingness and competence to sign the informed consent form
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.Previous or current DSM-5 axis-I disorder
•2.Fulfilment of the criteria for dementia
•3.Evidence of previous or current significant neurological disorder
•4.Significant medical illness relevant for this study
•5.Use of prohibited concomitant medication (see section 9.1.8)
•6.Women with childbearing potential
•7.Reversible causes for memory impairment
•8.Pace makers, cochlear implants, insulin pumps, other implants made of ferromagnetic materials

发起方